Fig. 3From: Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesNo correlation between the 94-SNP risk score and pathological subtype of breast cancer. SNP single nucleotide polymorphism, ER estrogen receptor, HER2 human epidermal growth factor, ANOVA analysis of varianceBack to article page